Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 601–700 of 1,000
Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?
D'Arena, G. F., Simeon, V., D’Auria, F., Statuto, T., Sanzo, P. D., Martino, L. D., Marandino, A., Sangiorgio, M., Musto, P., & Feo, V. D. (2013) · Europe PMC (PubMed Central) · Cited by 35
Effect of CpG ODN on monocytic myeloid derived suppressor cells
Shirota, H., & Klinman, D. M. (2012) · OncoImmunology · doi:10.4161/onci.19731 · Cited by 26
“The tumor microenvironment plays a role in this failure, as large tumors contain regulatory T cells and myeloid-derived suppressor cells (MDSC) that interfere with the lytic activity of CTL and NK cells.(5) MDSC are particularly problematic, as they typically constitute a majority of all tumor infiltrating cells.”
BackgroundAbagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer
Grisham, R. N., Berek, J. S., Pfisterer, J., & Sabbatini, P. J. (2011) · Immunotherapy · doi:10.2217/imt.10.100 · Cited by 26
Hughes, J., Wang, P., Alusi, G., Shi, H., Chu, Y., Wang, J., Bhakta, V., McNeish, I. A., McCart, A., Lemoine, N. R., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.13 · Cited by 25
Vargas, F. A., Kochan, G. T., Breckpot, K., Stephenson, H. N., & Escors, D. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012798764679 · Cited by 28
“uk immune response and promote angiogenesis, such as IL-10 and TGF- [14].”
BackgroundChen, P., Wang, C., Cheng, B., Nesa, E. U., Liu, Y., Jia, Y., Qu, Y., Jiang, Z., Han, J., & Cheng, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s138854 · Cited by 26
“The roles of malnutrition and inflammation in regulating carcinogenesis, tumor progression, and metastasis have become the hot spot in cancer research.(1,5,23) Low serum albumin could represent the compromised nutritional status of the host, as well as the response of systemic inflammation.”
Immune cells as anti‐cancer therapeutic targets and tools
Johansson, M., Tan, T., de Visser, K. E., & Coussens, L. M. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21230 · Cited by 28
“Indeed, individuals suffering from various types of immune-deficiency disorders exhibit increased risk for someviral- and/or carcinogenassociated cancers [Zitvogel et al., 2006], thus indicating that absence of anti-viral immunity has effected their relative cancer risk.”
BackgroundUse of Immunosuppressants and Biologicals in Patients with Previous Cancer
Beaugerie, L. (2013) · Digestive Diseases · doi:10.1159/000353382 · Cited by 24
PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Bagley, S. J., Bauml, J. M., & Langer, C. J. (2015) · PubMed · Cited by 30
Cao, D., Chen, M., Zhang, Q.-F., Zhou, Y.-F., Zhang, M., Mai, S., Zhang, Y., Chen, M., Li, X., & Wang, H. (2020) · Aging · doi:10.18632/aging.103395 · Cited by 30
“not sensed and destroyed by the immunosystem [6].”
BackgroundLomboy Kristoffersen Edward Mayce, R., & Hernandez, R. (2021) · International Journal of Advanced Technology and Engineering Exploration · doi:10.19101/ijatee.2021.874380 · Cited by 26
“have established that both cancer cells and noncancer cells with a significant amount are the recipes for the heterocellular tumor are involved in tumor development and malignancy [2, 3].”
BackgroundLin, Z., Huang, Q., Liu, J., Wang, H., Zhang, X., Zhu, Z., Zhang, W., Wei, Y., Liu, Z., & Du, W. (2022) · Aging · doi:10.18632/aging.204208 · Cited by 27
Circulating apoptotic markers in the management of non-small cell lung cancer
Holdenrieder, S., & Stieber, P. (2010) · Cancer Biomarkers · doi:10.3233/cbm-2009-0130 · Cited by 29
“by reducing specific surface ligands and subsequently by directly attacking immune cells [5,85,150,199,200].”
Dual function of MyD88 in inflammation and oncogenesis: implications for therapeutic intervention
Kfoury, A., Virard, F., Renno, T., & Coste, I. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000037 · Cited by 28
Immune Therapy for Ovarian Cancer: Promise and Pitfalls
Thibodeaux, S. R., & Curiel, T. J. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2011.567361 · Cited by 27
“Tumors can also prevent tumor-specific immunity from eliminating tumors by inducing tumor-specific tolerance or inflammation (reviewed in [21, 23, 24]).”
BackgroundWu, S., Lu, X., Zhang, Z. L., Lei, P., Yu, Y., Wang, M., Huang, B., Xing, W., Jiang, X., Liu, H. J., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq265 · Cited by 24
“inhibit host anti-tumor immune response [7].”
Potential therapeutic role of natural killer cells in cancer
Woan, K. V., & Reddy, V. S. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.17 · Cited by 26
“Moreover, infected, oncogenic and stressed cells in general have been found to express aberrant surface antigens [3,49].”
BackgroundUllrich, F., Bröckelmann, P. J., Turki, A. T., Khan, A., Chiru, E.-D., Vetter, M. H. F., von Tresckow, B., Wirth, R., Córdoba, R., Ortiz‐Maldonado, V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009462 · Cited by 29
“41 As Open access the adaptive immune response to malignancy requires a sufficient pool of naïve T cells, the increased incidence of cancer with aging is a rational consequence of immunose-nescence.”
Intratumoral therapies and in-situ vaccination for melanoma
Huppert, L. A., & DAUD, A. I. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1890512 · Cited by 27
“Tumor infiltrating lymphocytes (TILs) in the TME can also initiate a positive feedback loop, secreting cytokines such as Interferon-γand Interleukin-12 (IL12) to help recruit effector T cells.(7) Indeed, the presence of TILs is associated with improved clinical response to immunotherapy.”
Backgroundde Kruijf, E. M., Engels, C. C., van de Water, W., Bastiaannet, E., Smit, V. T. H. B. M., van de Velde, C. J. �., Liefers, G., & Kuppen, P. J. K. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2752-2 · Cited by 29
Serba, S., Schmidt, J., Wentzensen, N., Ryschich, E., & Märten, A. (2007) · Gut · doi:10.1136/gut.2007.130252 · Cited by 24
Radiotherapy and Immunotherapy: Improving Cancer Treatment through Synergy
Reynders, K., & Ruysscher, D. D. (2015) · Progress in tumor research · doi:10.1159/000437185 · Cited by 24
Primary pancreatic lymphoma: two case reports and a literature review
Yu, L., Chen, Y., & Xing, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s121521 · Cited by 24
Duechler, M., Stańczyk, M. B., Czyż, M., & Stepnik, M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0527-3 · Cited by 24
“Second, necrosis is known to be immunogenic in contrast to apoptosis, which often is not [43].”
BackgroundRetroviral Replicating Vectors in Cancer
Logg, C. R., Robbins, J. M., Jolly, D. J., Gruber, H. E., & Kasahara, N. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00011-9 · Cited by 26
Kan, L. L., Chan, B. C.-L., Leung, P., & Wong, C. K. (2023) · Molecules · doi:10.3390/molecules28155804 · Cited by 25
“However, cancer cells can shed NKG2D ligands into a soluble form to escape detection before undergoing immunoediting and immunosubversion [40,41].”
BackgroundRON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses
Eyob, H., Ekiz, H. A., & Welm, A. L. (2013) · OncoImmunology · doi:10.4161/onci.25670 · Cited by 23
“The microenvironment of primary neoplastic lesions is particularly immunosuppressive, featuring increased levels of cytokines and mediators that inhibit CD8 T-cell responses, such as arginase and interleukin (IL)-10.(8) However, tumor cells that have invaded a new microenvironment may be more vulnerable to immunosurve…”
Casey, S. C., Li, Y., & Felsher, D. W. (2014) · Immunologic Research · doi:10.1007/s12026-014-8503-6 · Cited by 23
“Similarly, the immune system appears to play a role in the mechanism by which therapeutics prompt tumor regression [75, 81].”
BackgroundImmune alterations in malignant melanoma and current immunotherapy concepts
Shimanovsky, A., Jethava, A., & Dasanu, C. A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.827658 · Cited by 27
“The ability of the tumor microenvironment to modulate and suppress the host immune response is a key element in cancer biology [10].”
BackgroundSahin, M. A., Şahın, E., & Köksoy, S. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.05.009 · Cited by 23
Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0419-z · Cited by 25
Olsen, C., Hyrich, K., Knight, L. L., & Green, A. (2016) · Melanoma research · doi:10.1097/cmr.0000000000000284 · Cited by 17
Could the menagerie of the gut microbiome really cure cancer? Hope or hype
Abid, M. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0561-9 · Cited by 25
Amin, A., Mokhdomi, T. A., Bukhari, S., Wani, Z. A., Chikan, N. A., Shah, B. A., Koul, A. M., Majeed, U., Farooq, F., Qadri, A., et al. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29883 · Cited by 25
Karlsen, M., Hovden, A., Vogelsang, P., Tysnes, B. B., & Appel, S. (2011) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2011.02562.x · Cited by 23
Anti-tumor immunity: Myeloid leukocytes control the immune landscape
Rutkowski, M. R., Stephen, T. L., & Conejo-Garcia, J. R. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.06.014 · Cited by 28
“However, despite the fact that immune system can mount strong anti-tumor responses, tumors still evade the immune pressure [31].”
BackgroundMetabolism, LXR/LXR ligands, and tumor immune escape
Russo, V. E. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411198 · Cited by 26
“), which in theory, should be detrimental for tumor growth [5, 6].”
BackgroundTRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer
Wei, B., Liang, J., Hu, J., Mi, Y., Ruan, J., Zhang, J., Wang, Z., Hu, Q., Jiang, H., & Ding, Q. (2017) · Medical Science Monitor · doi:10.12659/msm.903500 · Cited by 31
de Groot, A. F., Blok, E. J., Charehbili, A., Engels, C. C., Smit, V. T. H. B. M., Dekker-Ensink, N. G., Putter, H., Kranenbarg, E. M., van de Velde, C. J. �., Liefers, G., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05195-y · Cited by 23
Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications
Wang, Y., Zhao, B., Chen, W., Liu, L., Chen, W., Zhou, L., Kong, Z., Dai, C., Wang, Y., & Ma, W. (2020) · Aging and Disease · doi:10.14336/ad.2019.0527 · Cited by 24
“Inflammatory factors, such as C-reactive protein and serum albumin, are also reliable and sensitive indicators of the acute response of tumor cells to proper interventions [39].”
BackgroundThe natural killer cell: a further innate mediator of gouty inflammation?
Empson, V. G., McQueen, F. M., & Dalbeth, N. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.91 · Cited by 27
Utility of Clostridium difficile Toxin B for Inducing Anti-Tumor Immunity
Huang, T., Li, S., Li, G., Tian, Y., Wang, H., Shi, L., Pérez‐Cordón, G., Mao, L., Wang, X., Wang, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110826 · Cited by 23
“The utilization of immunogenic properties of cancer cell death has been considered as an ideal strategy to improve the outcome of cancer therapy [22,23,42], and previous study showed that some chemical drugs have an ability to induce immunogenic death of tumor cells [27,28].”
BackgroundThe Hallmarks of Cancer as Eco-Evolutionary Processes
Bhattacharya, R., Avdieiev, S. S., Bukkuri, A., Whelan, C. J., Gatenby, R. A., Tsai, K. Y., & Brown, J. S. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0861 · Cited by 26
Kötting, C., Hofmann, L., Lotfi, R., Engelhardt, D., Laban, S. A., Schuler, P. J., Hoffmann, T. K., Brunner, C., & Theodoraki, M. (2021) · Cancers · doi:10.3390/cancers13061335 · Cited by 28
“While an increased occurrence of Treg is noticed in the TME of most malignant cancers [47], a predominance of elevated CTL levels is associated with better tumor-specific immune response and superior patient outcomes [48].”
BackgroundNatural killer cell therapy: A new frontier for obesity-associated cancer
Mylod, E., Lysaght, J., & Conroy, M. J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215620 · Cited by 22
Liu, X., Chen, Y., Fu, Y., Jiang, D., Gao, F., Tang, Z., Bian, X., Wu, S., Yu, Y., Wang, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01446 · Cited by 23
Lei, J., Rudolph, A., Moysich, K. B., Rafiq, S., Behrens, S., Goode, E. L., Pharoah, P. D. P., Seibold, P., Fasching, P. A., Andrulis, I. L., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0522-2 · Cited by 25
“Genes related to Treg cell and MDSC pathways were identified through an extensive and comprehensive literature review in PubMed [22-34], using the search terms immunosuppression/immunosuppressive, regulatory T cells/Treg cells/FOXP3+ T cells, myeloid derived suppressor cells/MDSCs, immunosurveillance, and tumor escape…”
BackgroundSolannm lyratum extract affected immune response in normal and leukemia murine animal in vivo
Yang, J., Wu, C., Kuo, C., Yeh, C.-C., Chueh, F., Hsu, C., Wang, C., Chang, C.-Y., Ip, S., Hsu, Y., et al. (2010) · Human & Experimental Toxicology · doi:10.1177/0960327110364153 · Cited by 22
“Tumors can evade the immune system including reduced immunogenicity of host, resistance to killing by immune effector cells or subversion of the immune response.(25) The relationship between cancers and the immune system will guide the design of future therapeutic strategies.”
BackgroundThe Role of Oncolytic Virus Immunotherapies to Subvert Cancer Immune Evasion
Workenhe, S. T., Verschoor, M. L., & Mossman, K. L. (2015) · Future Oncology · doi:10.2217/fon.14.254 · Cited by 25
Bücklein, V., Adunka, T., Mendler, A. N., Issels, R. D., Subklewe, M. S., Schmollinger, J. C., & Noeßner, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1178421 · Cited by 24
“NK cells and CD8C T lymphocytes can act as major players in antitumor responses, and inhibition of their function has been associated with tumor immune escape.(39,40) Here, we examined the NK cell-specific cytotoxicity of PBMCs of patients with STS and RCC in comparison with healthy controls, and aimed to identify dif…”
BackgroundExpression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung
Sterlacci, W., Fiegl, M., Droeser, R. A., & Tzankov, A. (2016) · Pathobiology · doi:10.1159/000444804 · Cited by 24
Koch, C., Kim, Y.-H., Zöller, T., Born, C., & Steinle, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01466 · Cited by 23
Normalization Cancer Immunotherapy for Melanoma
Vesely, M. D., & Chen, L. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.005 · Cited by 25
“This latter event frequently leads to formation of an immunosuppressive TME that inhibits subsequent naturally occurring immune responses and resistance to immunotherapy (Sharma et al., 2017a; Zitvogel et al., 2006).”
BackgroundNiccolai, E., Boem, F., Emmi, G., & Amedei, A. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.03.001 · Cited by 23
Verma, A., Lam, Y. M., Leung, Y., Hu, X., Chen, X., Cheung, E. C. W., & Tam, K. Y. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13033 · Cited by 22
“Cancer cells differ from healthy cells due to a plethora of molecular changes.([4,5]) Many of these molecular changes may be mechanistically linked to metabolic reprogramming, which helps the cancer cells to adapt to the hypoxic and nutrient-deprived tumour microenvironment.”
BackgroundTumor-derived Exosomes and Antitumor Immunity
Whiteside, T. L. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400335 · Cited by 25
Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
Ryba-Stanisławowska, M. E. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00992-0 · Cited by 26
“Additionally, tumour-specific antibodies may induce anti - body-dependent cytotoxicity (ADCC) and tumour clearance [47].”
Tumor microenvironment in osteosarcoma: From cellular mechanism to clinical therapy
Yu, Y., Li, K., Peng, Y., Zhang, Z., Pu, F., Shao, Z., & Wu, W. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101569 · Cited by 39
Berndt, U., Philipsen, L., Bartsch, S., Yu-qin, H., Röcken, C., Wiedenmann, B., Hämmerle, M., Rösch, T., & Sturm, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-177 · Cited by 22
“T cells have the ability to recognize oncogenic precursor signals and thus prevent malignant tissue transformation [28].”
BackgroundCalmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Cruz, M. T., Falcão, A. C., & Neves, B. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105309 · Cited by 22
A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy
Lagou, M. K., Anastasiadou, D. P., & Karagiannis, G. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933547 · Cited by 22
Castagnoli, F., Doran, S., Lunn, J., Minchom, A. R., O'Brien, M. E. R., Popat, S., Messiou, C., & Koh, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270950 · Cited by 23
Engels, C. C., Fontein, D. B. Y., Kuppen, P. J. K., de Kruijf, E. M., Smit, V. T. H. B. M., Nortier, J. W. R., Liefers, G., van de Velde, C. J. �., & Bastiaannet, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.338 · Cited by 27
“However, there is also strong evidence that the BC host’s adaptive immune system plays a crucial role in the control of tumour growth and progression (Zitvogel et al, 2006).”
BackgroundEddine, F. B. N., Ramia, E., Tosi, G., Forlani, G., & Accolla, R. S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356149 · Cited by 25
“invisible to the immune system and consequently being able to escape, progress and spread.(5,6) In the tumor microenvironment, tumor cells may secrete immunosuppressive cytokines like Tumor Growth Factor b (TGFb) and Vascular Endothelial Growth Factor (VEGF),(7) recruit regulatory T cells with suppressive function (Tr…”
BackgroundSchirrmacher, V., Schlude, C., Weitz, J., & Beckhove, P. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2692 · Cited by 22
Kowalski, R. J., Zeevi, A., Mannon, R. B., Britz, J. A., & Carruth, L. M. (2007) · Journal of Immunotoxicology · doi:10.1080/15476910701385638 · Cited by 21
“Similarly, suppression of the immune system in transplant and cancer, or infection such as Human Immunodeficiency Virus (HIV) and Hepatitis C leaves the host vulnerable to opportunistic infections (OIs), cardiovascular disease and cancer (Rosen and Narasimhan, 2006; Zitvogel et al., 2006).”
BackgroundImmune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies
Ring, K. L., Pakish, J. B., & Jazaeri, A. A. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000179 · Cited by 21
Hirai, H., Tomioka, H., Mochizuki, Y., Oikawa, Y., Tsushima, F., & Harada, H. (2017) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2017.01.006 · Cited by 20
Huang, B. Y., Bai, Z., Ye, X., Zhou, C., Xie, X., Zhong, Y., Lin, K., & Ma, L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.036 · Cited by 21
“Herein, the immune checkpoint plays a central role in tissue homeostasis self-reactivity and autoimmunity, which targets the innate and adaptive immune systems [6], and is the signal recognition factor for immunosurveillance in immune cells [7].”
BackgroundLi, Y., Ruan, S., Guo, J., He, Z., Xia, Q., Wu, T. S., Wang, Z., Li, Z., Hu, H., Jing, Q., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00212 · Cited by 21
GAUDIO, A. D., Vincenzo, F. D., Petito, V., Giustiniani, M. C., Gasbarrini, A., Scaldaferri, F., & Lopetuso, L. R. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad229 · Cited by 24
Interactions between platelets and the cancer immune microenvironment
Tuerhong, N., Yang, Y., Wang, C., Huang, P., & Li, Q. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104380 · Cited by 23
The Evolution of Microfluidic‐Based Drug‐Loading Techniques for Cells and Their Derivatives
Tong, S., Niu, J., Wang, Z., Jiao, Y., Fu, Y., Li, D., Pan, X., Sheng, N., Li, Y., Min, P., et al. (2024) · Small · doi:10.1002/smll.202403422 · Cited by 22
Tandon, M., Vemula, S. V., Sharma, A., Ahi, Y. S., Mittal, S., Bangari, D. S., & Mittal, S. K. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.1649 · Cited by 20
“as one of the hallmarks of cancer [63].”
BackgroundPancreatic Cancer Alters Human CD4+ T Lymphocyte Function: A Piece in the Immune Evasion Puzzle
Fogar, P., Basso, D., Fadi, E., Greco, E., Pantano, G., Padoan, A., Bozzato, D., Facco, M., Sanzari, M. C., Teolato, S., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e31822077b8 · Cited by 24
Role of stress‐induced NKG2D ligands in liver diseases
Kahraman, A., Fingas, C. D., Syn, W., Gerken, G., & Canbay, A. E. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02608.x · Cited by 21
Cancer Prevention: Lessons Learned and Future Directions
Dunn, B. K., & Kramer, B. S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.003 · Cited by 21
Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer
Hu, J., Hu, J., Liu, X., Hu, C., Li, M., & Han, W. (2017) · Medicine · doi:10.1097/md.0000000000008310 · Cited by 20
CRTAM+ NK cells endowed with suppressor properties arise in leukemic bone marrow
Ramírez-Ramírez, D., Padilla-Castañeda, S., Galán-Enríquez, C. S., Vadillo, E., Prieto‐Chávez, J. L., Jiménez‐Hernández, E., Vilchis-Ordóñez, A., Sandoval-Cabrera, A., Balandrán, J. C., Pérez‐Tapia, S. M., et al. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.ma0618-231r · Cited by 25
Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword
Huang, Q., Cao, W. H. J., Mielke, L. A., Seillet, C., Belz, G. T., & Jacquelot, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03080 · Cited by 21
Ogony, J. W., Radisky, D. C., Ruddy, K. J., Goodison, S., Wickland, D. P., Egan, K. M., Knutson, K. L., Asmann, Y. W., & Sherman, M. E. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-19-0562 · Cited by 22
“Microsatellite instability reflects a predisposition to mutation from impaired DNA mismatch repair, and accumulation of tumor cells with microsatellite instability could indicate deficiencies in tumor immunosurveillance and failure to eliminate such clones prior to cancer development (15).”
BackgroundEvidence for Immunosurveillance in Intestinal Premalignant Lesions
Karlsson, M. K., Lindberg, K. A., Karlén, P., Öst, Å., Thörn, M., Winqvist, O., & Eberhardson, M. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02377.x · Cited by 20
Liu, J., Li, X.-Y., Yu, H., Yang, G., Liu, Z., Geng, X., Wang, S., Mo, L., Zeng, L., Zhao, M., et al. (2015) · Scientific Reports · doi:10.1038/srep10665 · Cited by 25
RetractedCritical role for CD8 + FoxP3 + regulatory T cells in colon cancer immune response in humans
Sobhani, I., & Gouvello, S. L. (2009) · Gut · doi:10.1136/gut.2008.175521 · Cited by 20
“interleukin 10 (IL10), colony-stimulating factor-1 (CSF-1) and vascular endothelial factor (VEGF)).(3)”
BackgroundZhang, Y., Zhang, Y., Song, J., Cheng, X., Zhou, C., Huang, S., Zhao, W., Zong, Z., & Yang, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111876 · Cited by 22
Micronutrient Status and Breast Cancer: A Narrative Review
Forma, A., Grunwald, A., Zembala, P., Januszewski, J., Brachet, A., Zembala, R., Świątek, K., & Baj, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094968 · Cited by 29
“A key mechanism used by cancer cells to suppress the immunological response is the sequestration of dendritic cells (DCs) to inhibit their mobility [19].”
BackgroundZhang, F., Zhang, J., Liu, M., Zhao, L., Linghu, R., Feng, F., Gao, X., Jiao, S., Zhao, L., Hu, Y., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994391 · Cited by 19
Treatment of spinal metastases in renal cell carcinoma: A critical review
Teyssonneau, D., Gross‐Goupil, M., Domblides, C., Haaser, T., Pointillart, V., Daste, A., Hauger, O., & Ravaud, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.02.017 · Cited by 22
T-cell trafficking plays an essential role in tumor immunity
Aires, D., Yoshida, M., Richardson, S. K., Bai, M., Liu, L., Moreno, R., Lazar, A. J., Wick, J., Rich, B. E., Murphy, G. F., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0124-6 · Cited by 19
“Naïve T cells express α4β7 at low levels, but α4β7 is much more highly expressed by effector and memory cells generated in gut-draining lymphoid tissue; these latter T cells selectively traffic to the laminia propria in the GI tract [8].”
BackgroundFlores-Hidalgo, A., Murrah, V. A., Fedoriw, Y. D., & Padilla, R. J. (2019) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2019.02.004 · Cited by 20
The Origin and Role of MHC Class I-Associated Self-Peptides
Perreault, C. (2010) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(10)92003-6 · Cited by 22
A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination
Rafi, M. A., & Omidi, Y. (2015) · Bioimpacts · doi:10.15171/bi.2015.22 · Cited by 19
“BioImpacts, 2015, 5(3), 117-122 118 machineries are known as exosomes (EXOs) and ectosomes (ECTOs), which are micro-/nano-scaled vesicles secreted from various cells to convey messages related to immune responses and signal transductions.”
BackgroundInfluentialVitale, G., Lupoli, G., Guarrasi, R., Colao, A., Dicitore, A., Gaudenzi, G., Misso, G., Castellano, M., Addeo, R., Facchini, G., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1443 · Cited by 19
“However, tumors often avoid surveillance of the immune system through several mechanisms (26).”
BackgroundCâncer e o microambiente tumoral
Onuchic, A. C., & Chammas, R. J. (2010) · Revista de Medicina · doi:10.11606/issn.1679-9836.v89i1p21-31 · Cited by 70
Warming up the tumor microenvironment in order to enhance immunogenicity
Humbert, M., & Hugues, S. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1510710 · Cited by 18
“The tumor microenvironment (TME) however negatively impacts the immune system through three main mechanisms, namely immunosuppression, immunoevasion and immunoediting.(2) Thesemechanisms involve cancer and mesenchymal cells, as well as immune cells, such as myeloid-derived suppressor cells, regulatory T cells (Tregs),…”
BackgroundEngineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy
Liu, Z., Guo, C., Das, S. K., Yu, X., Pradhan, A. K., Li, X., Ning, Y., Chen, S., Liu, W., Windle, J. J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2604 · Cited by 19
“Accumulating clinical and preclinical evidence suggests that this partially results from heterogeneous expression of tumor antigens, immune evasion caused by immuno-editing, for example, selection of nonimmunogenic or antigen loss cancer cell variants (12, 13), a lack of sufficient specificity or numbers of TILs (14),…”
BackgroundImmunogenic chemotherapy: great potential for improving response rates
Huang, X., Ren, Q., Yang, L., Cui, D., Ma, C., Zheng, Y., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1308681 · Cited by 22
“In addition, chemotherapy treatment increases the expression level of tumor neo-antigen and MHC-I molecules on the surface of tumor cells (4).”
BackgroundInfluentialAn antitumor arabinan from Glehnia littoralis activates immunity and inhibits angiogenesis
Liu, W., Li, K., Zhang, H., Li, Y., Lin, Z., Xu, J., & Guo, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130242 · Cited by 20
Kang, Q., He, L., Zhang, Y., Zhong, Z., & Tan, W. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155684 · Cited by 23
Ziogas, D. C., Theocharopoulos, C., Aravantinou-Fatorou, K., Boukouris, A. E., Stefanou, D. T., Anastasopoulou, A. N., Lialios, P., Lyrarakis, G., & Gogas, H. J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104635 · Cited by 23
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.